Publication | Closed Access
3-Substituted 5,7-dimethylpyrazolo[1,5-a]pyrimidines, 3',5'-cyclic AMP phosphodiesterase inhibitors
73
Citations
0
References
1974
Year
Pharmaceutical ScienceAltmetric Attention ScorePharmacotherapyHeterocycle ChemistryChemical BiologyPharmaceutical ChemistryPre-clinical PharmacologyMolecular PharmacologyMedicinal ChemistryTherapeutic Drug MonitoringBiochemistrySocial Media PresenceDrug DevelopmentPharmacologyDonut IconNatural SciencesRational Drug DesignMedicineDrug DiscoveryQuantitative Pharmacology
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXT3-Substituted 5,7-dimethylpyrazolo[1,5-a]pyrimidines, 3',5'-cyclic AMP phosphodiesterase inhibitorsThomas Novinson, Ruth Hanson, M. K. Dimmitt, Lionel N. Simon, Roland K. Robins, and Darrell E. O'BrienCite this: J. Med. Chem. 1974, 17, 6, 645–648Publication Date (Print):June 1, 1974Publication History Published online1 May 2002Published inissue 1 June 1974https://pubs.acs.org/doi/10.1021/jm00252a016https://doi.org/10.1021/jm00252a016research-articleACS PublicationsRequest reuse permissionsArticle Views229Altmetric-Citations66LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose Get e-Alerts